RenovoRx Inc
RNXT0.930USD
+0.030+3.33%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
34.08MMarket Cap
LossP/E TTM
More Details of RenovoRx Inc Company
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
RenovoRx Inc Info
Ticker SymbolRNXT
Company nameRenovoRx Inc
IPO dateAug 17, 2021
CEOBagai (Shaun R)
Number of employees10
Security typeOrdinary Share
Fiscal year-endAug 17
Address2570 W. El Camino Real, Ste. 320,
CityMOUNTAIN VIEW
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94040
Phone14088002649
Websitehttps://renovorx.com/
Ticker SymbolRNXT
IPO dateAug 17, 2021
CEOBagai (Shaun R)
Company Executives of RenovoRx Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Robert J. (Bob) Spiegel, M.D.
Dr. Robert J. (Bob) Spiegel, M.D.
Independent Director
Independent Director
40.98K
--
Ms. Kirsten Angela Macfarlane
Ms. Kirsten Angela Macfarlane
Independent Director
Independent Director
40.98K
--
Mr. Valter Pinto
Mr. Valter Pinto
Investor Relations
Investor Relations
--
--
Dr. Laurence J. Marton, M.D.
Dr. Laurence J. Marton, M.D.
Independent Director
Independent Director
--
--
Ms. Leesa Gentry
Ms. Leesa Gentry
Chief Clinical Officer
Chief Clinical Officer
--
--
Dr. Ramtin Agah, M.D.
Dr. Ramtin Agah, M.D.
Chairman of the Board, Co-Founder, Chief Medical Officer
Chairman of the Board, Co-Founder, Chief Medical Officer
--
--
Dr. Una S. Ryan, Ph.D.
Dr. Una S. Ryan, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Ronald B. (Ron) Kocak, CPA
Mr. Ronald B. (Ron) Kocak, CPA
Principal Financial Officer and Accounting Officer, Vice President, Controller
Principal Financial Officer and Accounting Officer, Vice President, Controller
--
--
Mr. Shaun R. Bagai
Mr. Shaun R. Bagai
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Robert J. (Bob) Spiegel, M.D.
Dr. Robert J. (Bob) Spiegel, M.D.
Independent Director
Independent Director
40.98K
--
Ms. Kirsten Angela Macfarlane
Ms. Kirsten Angela Macfarlane
Independent Director
Independent Director
40.98K
--
Mr. Valter Pinto
Mr. Valter Pinto
Investor Relations
Investor Relations
--
--
Dr. Laurence J. Marton, M.D.
Dr. Laurence J. Marton, M.D.
Independent Director
Independent Director
--
--
Ms. Leesa Gentry
Ms. Leesa Gentry
Chief Clinical Officer
Chief Clinical Officer
--
--
Dr. Ramtin Agah, M.D.
Dr. Ramtin Agah, M.D.
Chairman of the Board, Co-Founder, Chief Medical Officer
Chairman of the Board, Co-Founder, Chief Medical Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
AIGH Capital Management, LLC.
5.25%
The Vanguard Group, Inc.
4.38%
Agah (Ramtin M.D.)
3.22%
AWM Investment Company, Inc.
2.36%
Worth Venture Partners, LLC
1.89%
Other
82.91%
Shareholders
Shareholders
Proportion
AIGH Capital Management, LLC.
5.25%
The Vanguard Group, Inc.
4.38%
Agah (Ramtin M.D.)
3.22%
AWM Investment Company, Inc.
2.36%
Worth Venture Partners, LLC
1.89%
Other
82.91%
Shareholder Types
Shareholders
Proportion
Investment Advisor
6.87%
Investment Advisor/Hedge Fund
5.49%
Private Equity
5.25%
Individual Investor
4.55%
Hedge Fund
1.45%
Bank and Trust
0.27%
Venture Capital
0.09%
Research Firm
0.05%
Other
75.99%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
47
8.06M
22.01%
-3.57M
2025Q2
51
11.72M
32.06%
+5.26M
2025Q1
52
10.53M
29.46%
+6.73M
2024Q4
39
1.47M
4.14%
-2.25M
2024Q3
38
2.35M
9.16%
-392.19K
2024Q2
40
2.34M
14.23%
-1.80M
2024Q1
36
1.98M
17.38%
-1.99M
2023Q4
40
1.81M
16.91%
-1.93M
2023Q3
39
3.15M
32.01%
-2.10M
2023Q2
36
3.04M
31.03%
-2.11M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
AIGH Capital Management, LLC.
2.59M
7.08%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
1.66M
4.54%
+317.89K
+23.62%
Jun 30, 2025
Agah (Ramtin M.D.)
1.13M
3.1%
+21.00K
+1.89%
Jun 05, 2025
AWM Investment Company, Inc.
1.87M
5.1%
-414.77K
-18.15%
Jun 30, 2025
Worth Venture Partners, LLC
873.61K
2.38%
--
--
Jun 30, 2025
Bleichroeder LP
500.00K
1.36%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
353.60K
0.96%
+31.73K
+9.86%
Jun 30, 2025
Bagai (Shaun R.)
330.04K
0.9%
+10.00K
+3.12%
Aug 25, 2025
Renaissance Technologies LLC
251.80K
0.69%
+224.14K
+810.47%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of RenovoRx Inc?
The top five shareholders of RenovoRx Inc are:
AIGH Capital Management, LLC. holds 2.59M shares, accounting for 7.08% of the total shares.
The Vanguard Group, Inc. holds 1.66M shares, accounting for 4.54% of the total shares.
Agah (Ramtin M.D.) holds 1.13M shares, accounting for 3.10% of the total shares.
AWM Investment Company, Inc. holds 1.87M shares, accounting for 5.10% of the total shares.
Worth Venture Partners, LLC holds 873.61K shares, accounting for 2.38% of the total shares.
AIGH Capital Management, LLC. holds 2.59M shares, accounting for 7.08% of the total shares.
The Vanguard Group, Inc. holds 1.66M shares, accounting for 4.54% of the total shares.
Agah (Ramtin M.D.) holds 1.13M shares, accounting for 3.10% of the total shares.
AWM Investment Company, Inc. holds 1.87M shares, accounting for 5.10% of the total shares.
Worth Venture Partners, LLC holds 873.61K shares, accounting for 2.38% of the total shares.
What are the top three shareholder types of RenovoRx Inc?
The top three shareholder types of RenovoRx Inc are:
AIGH Capital Management, LLC.
The Vanguard Group, Inc.
Agah (Ramtin M.D.)
AIGH Capital Management, LLC.
The Vanguard Group, Inc.
Agah (Ramtin M.D.)
How many institutions hold shares of RenovoRx Inc (RNXT)?
As of 2025Q3, 47 institutions hold shares of RenovoRx Inc, with a combined market value of approximately 8.06M, accounting for 22.01% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -10.05%.
What is the biggest source of revenue for RenovoRx Inc?
In --, the -- business generated the highest revenue for RenovoRx Inc, amounting to -- and accounting for --% of total revenue.
